Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder

被引:21
|
作者
Foa, Edna B. [1 ]
Simpson, Helen Blair [2 ,3 ]
Rosenfield, David [4 ]
Liebowitz, Michael R. [3 ]
Cahill, Shawn P. [6 ]
Huppert, Jonathan D. [1 ,7 ]
Bender, James, Jr. [2 ]
McLean, Carmen P. [1 ]
Maher, Michael J. [2 ]
Campeas, Raphael [2 ,3 ]
Hahn, Chang-Gyu [1 ]
Imms, Patricia [1 ]
Pinto, Anthony [2 ,3 ]
Powers, Mark B. [5 ]
Rodriguez, Carolyn I. [2 ,3 ]
Van Meter, Page E. [2 ]
Vermes, Donna [2 ]
Williams, Monnica T. [8 ]
机构
[1] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[2] New York State Psychiat Inst & Hosp, Div Clin Therapeut, New York, NY 10032 USA
[3] Columbia Univ, Dept Psychiat, New York, NY USA
[4] So Methodist Univ, Dept Psychol, Dallas, TX 75275 USA
[5] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA
[6] Univ Wisconsin, Dept Psychol, Milwaukee, WI 53201 USA
[7] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel
[8] Univ Louisville, Dept Psychol & Brain Sci, Louisville, KY 40292 USA
关键词
COGNITIVE-BEHAVIORAL THERAPY; DOUBLE-BLIND; ANTIPSYCHOTIC AUGMENTATION; RATING-SCALE; FOLLOW-UP; NONRESPONDERS; RELIABILITY; MEDICATION; VALIDITY;
D O I
10.4088/JCP.14m09044
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Objective: To compare outcomes after 6-month maintenance treatment of adults diagnosed with obsessive-compulsive disorder (OCD) based on DSM-IV criteria who responded to acute treatment with serotonin reuptake inhibitors (SRIs) augmented by exposure and response prevention (EX/RP) or risperidone. Method: A randomized trial was conducted at 2 academic sites from January 2007 through December 2012. In the acute phase, 100 patients on therapeutic SRI dose with at least moderate OCD severity were randomized to 8 weeks of EX/RP, risperidone, or pill placebo. Responders entered the 6-month maintenance phase, continuing the augmentation strategy they received acutely (n = 30 EX/RP, n = 8 risperidone). Independent evaluations were conducted every month. The main outcome was the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Results: Intent-to-treat analyses indicated that, after 6-month maintenance treatment, EX/RP yielded OCD outcomes that were superior to risperidone (Y-BOCS = 10.95 vs 18.70; t(40) = 2.76, P =.009); more patients randomized to EX/RP met response criteria (Y-BOCS decrease >= 25%: 70% vs 20%; P < .001) and achieved minimal symptoms (Y-BOCS <= 12: 50% vs 5%; P < .001). During maintenance, OCD severity decreased slightly in both conditions (Y-BOCS decrease = 2.2 points, P = .020). Lower Y-BOCS at entry to maintenance was associated with more improvement in both conditions (r(38) = 0.57, P < .001). Conclusions: OCD patients taking SRIs who responded to acute EX/RP or risperidone maintained their gains over 6-month maintenance. Because EX/RP patients improved more during acute treatment than risperidone-treated patients, and both maintained their gains during maintenance, EX/RP yielded superior outcomes 6-months later. The findings that 50% of patients randomized to EX/RP had minimal symptoms at 6-month maintenance, a rate double that of prior studies, suggests that EX/RP maintenance helps maximize long-term outcome.
引用
收藏
页码:440 / 446
页数:7
相关论文
共 50 条
  • [1] Six-Month Follow-Up of a Randomized Controlled Trial Augmenting Serotonin Reuptake Inhibitor Treatment With Exposure and Ritual Prevention for Obsessive-Compulsive Disorder
    Foa, Edna B.
    Simpson, Helen Blair
    Liebowitz, Michael R.
    Powers, Mark B.
    Rosenfield, David
    Cahill, Shawn P.
    Campeas, Raphael
    Franklin, Martin
    Hahn, Chang-Gyu
    Hembree, Elizabeth A.
    Huppert, Jonathan D.
    Schmidt, Andrew B.
    Vermes, Donna
    Williams, Monnica T.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (05) : 464 - 469
  • [2] Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder A Randomized Clinical Trial
    Simpson, Helen Blair
    Foa, Edna B.
    Liebowitz, Michael R.
    Huppert, Jonathan D.
    Cahill, Shawn
    Maher, Michael J.
    McLean, Carmen P.
    Bender, James, Jr.
    Marcus, Sue M.
    Williams, Monnica T.
    Weaver, Jamie
    Vermes, Donna
    Van Meter, Page E.
    Rodriguez, Carolyn I.
    Powers, Mark
    Pinto, Anthony
    Imms, Patricia
    Hahn, Chang-Gyu
    Campeas, Raphael
    [J]. JAMA PSYCHIATRY, 2013, 70 (11) : 1190 - 1198
  • [3] Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: What Moderates Improvement?
    Wheaton, Michael G.
    Rosenfield, David
    Foa, Edna B.
    Simpson, H. Blair
    [J]. JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 2015, 83 (05) : 926 - 937
  • [4] Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder
    Hazari, Nandita
    Narayanaswamy, Janardhanan C.
    Arumugham, Shyam Sundar
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (10) : 1175 - 1191
  • [5] Effectiveness and tolerability of addition of risperidone in obsessive-compulsive disorder with poor response to serotonin reuptake inhibitors
    Horcajadas, F. Arias
    Soto, J. A.
    Garcia-Cantalapiedra, M. J.
    Rodriguez Calvin, J. L.
    Morales, J.
    Salgado, M.
    [J]. ACTAS ESPANOLAS DE PSIQUIATRIA, 2006, 34 (03): : 147 - 152
  • [6] Augmenting Selective Serotonin Reuptake Inhibitors With Clomipramine in Obsessive-Compulsive Disorder: Benefits and Risks
    Andrade, Chittaranjan
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (12) : E1128 - E1133
  • [7] Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: A crossover study
    Li, XH
    May, RS
    Tolbert, LC
    Jackson, WT
    Flournoy, JM
    Baxter, LR
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (06) : 736 - 743
  • [8] Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A six-month follow-up case series
    Dell'Osso, Bernardo
    Mundo, Emanuela
    Altamura, A. Carlo
    [J]. CNS SPECTRUMS, 2006, 11 (11) : 879 - 883
  • [9] Controlled trial of exposure and response prevention in obsessive-compulsive disorder
    Lindsay, M
    Crino, R
    Andrews, G
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1997, 171 : 135 - 139
  • [10] Efficacy and tolerance of risperidone addition in serotonin reuptake inhibitors (SRI) treatment for refractory obsessive-compulsive disorder
    Arias, E
    Soto, JA
    Garcia, MJ
    Rodríguez-Calvín, JL
    Morales, J
    Salgado, M
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S341 - S341